Cargando…
Time for an individualized approach to first-line management of follicular lymphoma
Follicular lymphoma is a heterogeneous B-cell lymphoma both in presentation and at progression. For most patients it is a chronic, relapsing indolent disease with overall survival expectations now potentially beyond 20 years. However, in a significant minority (~20%) who experience early progression...
Autores principales: | Cartron, Guillaume, Trotman, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719078/ https://www.ncbi.nlm.nih.gov/pubmed/34985230 http://dx.doi.org/10.3324/haematol.2021.278766 |
Ejemplares similares
-
Prospects in the management of patients with follicular lymphoma beyond first-line therapy
por: Qualls, David, et al.
Publicado: (2022) -
Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies
por: Rodgers, Thomas D., et al.
Publicado: (2021) -
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019) -
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
por: Feugier, Pierre, et al.
Publicado: (2019) -
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
por: Bachy, Emmanuel, et al.
Publicado: (2021)